Axovant Gene Therapies Ltd (AXGT)

[BioBuck33]

Phase 2 results show no clinically meaningful benefit. Advantage of running a large (600+ patient) P2 trial is seeing small p values suggesting + results. In reality, a 2 point difference (out of a possible 70!!!) vs aricept alone (placebo group) on the ADAS-cog is not meaningful to the average patient.

Some will argue any difference at all is meaningful in the treatment of this dreadful disease. However, check out the ADAS-cog yourself and experiment with what a 2 point difference really means.

ADAS-cog--> http://www.agedcaretests.com/ADAS-COG_sample.pdf

P2 results--> http://investors.axovant.com/~/media/Files/A/Axovant-IR/documents/corporate-presentation-may-2016.pdf